Last reviewed · How we verify
tremelimumab (anti-CTLA4)
tremelimumab (anti-CTLA4) is a Anti-CTLA4 monoclonal antibody Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Metastatic melanoma, Non-small cell lung cancer.
Tremelimumab is an anti-CTLA4 monoclonal antibody that blocks the CTLA-4 receptor, enhancing T-cell activation and proliferation.
Tremelimumab is an anti-CTLA4 monoclonal antibody that blocks the CTLA-4 receptor, enhancing T-cell activation and proliferation. Used for Metastatic melanoma, Non-small cell lung cancer.
At a glance
| Generic name | tremelimumab (anti-CTLA4) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Anti-CTLA4 monoclonal antibody |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to CTLA-4, tremelimumab prevents the receptor from downregulating T-cell activation, leading to increased immune response against cancer cells. This mechanism is thought to be particularly effective in tumors with high PD-L1 expression.
Approved indications
- Metastatic melanoma
- Non-small cell lung cancer
Common side effects
- Fatigue
- Rash
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (PHASE2)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (PHASE2)
- Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery (EARLY_PHASE1)
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer (EARLY_PHASE1)
- Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies (PHASE2)
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tremelimumab (anti-CTLA4) CI brief — competitive landscape report
- tremelimumab (anti-CTLA4) updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about tremelimumab (anti-CTLA4)
What is tremelimumab (anti-CTLA4)?
How does tremelimumab (anti-CTLA4) work?
What is tremelimumab (anti-CTLA4) used for?
Who makes tremelimumab (anti-CTLA4)?
What drug class is tremelimumab (anti-CTLA4) in?
What development phase is tremelimumab (anti-CTLA4) in?
What are the side effects of tremelimumab (anti-CTLA4)?
What does tremelimumab (anti-CTLA4) target?
Related
- Drug class: All Anti-CTLA4 monoclonal antibody drugs
- Target: All drugs targeting CTLA-4
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic melanoma
- Indication: Drugs for Non-small cell lung cancer
- Compare: tremelimumab (anti-CTLA4) vs similar drugs
- Pricing: tremelimumab (anti-CTLA4) cost, discount & access